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Abstract
Background: Heart failure (HF) is one of the leading causes of morbidity and mortality in South Korea. With the
rapidly aging population in the country, the prevalence of HF and its associated costs are expected to rise
continuously. This study was carried out to estimate the prevalence and economic burden of HF in order to
understand its impact on our society.
Methods: A prevalence-based, cost-of-illness study was conducted using the 2014 Health Insurance Review
and Assessment Service-National Patients Sample (HIRA-NPS) data. Adult HF patients were defined as those
aged ≥19 years who had at least one insurance claim record with a primary or secondary diagnosis of HF (ICD-10
codes of I11.0, I13.0, I13.2, and I50.x). The costs consist of direct costs (i.e., medical and non-medical costs) and
indirect costs (i.e., productivity loss cost due to morbidity and premature death). Subgroup analyses were
conducted by age group, history of HF hospitalization, and type of universal health security program enrolled in.
Results: A total of 475,019 adults were identified to have HF in 2014. The estimated prevalence rate of HF was
12.4 persons per 1,000 adults. According to the base cases and the extended definition of the cases, the annual
economic burden of HF from a societal perspective ranges from USD 1,414.0 to 1,560.5 for individual patients, and
from USD 752.8 million to 1,085.6 million for the country. A high percentage (68.5 %) of this socioeconomic burden
consist of medical costs, followed by caregiver’s cost (13.2 %), productivity loss costs due to premature death
(10.8 %) and morbidity (4.2 %), and transportation costs (3.4 %). The HF patients with prior hospitalization due to
HF annually spent 9.7 times more for National-Health-Insurance-covered medical costs compared to HF patients
who were not previously hospitalized.
Conclusions: In the present study, HF patients who were older and had a history of prior hospitalization for HF as
well as an indigent status were shown at high risk of spending more for healthcare to treat their HF. An effective
disease management protocol should be employed to target this patient group.
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Background
According to the American College of Cardiology
Foundation and American Heart Association [1], heart
failure (HF) is defined as “a complex clinical syndrome
that results from any structural or functional impair-
ment of the ventricular filling or ejection of blood”.
More than two-thirds of HF patients have underlying
diseases such as ischemic heart disease, chronic ob-
structive pulmonary disease, hypertensive heart disease,
and rheumatic heart disease [2]. The early symptoms of
HF include chronic fatigue, indigestion, insomnia, and
headache. Based on the progression of the disease, swell-
ing, ascites, and dyspnea due to lung congestion are
commonly developed.
HF is a progressive disease with repeated recurrences
and improvements, resulting in frequent hospitalization
[3]. It has been observed in Minnesota, U.S. that
about 16.5 % of HF patients experience at least one
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hospitalization associated with HF during their lifetime,
and that 83.1 % are hospitalized for all types of reasons
[4]. Roughly one in four HF patients among the Medicaid
beneficiaries in the U.S. is readmitted within a month after
discharge with HF [5]. In particular, among those 65 years
or older, HF is the most common reason for hos-
pitalization [6]. Whellan et al. reported that 66 % of the
elderly in their study who were hospitalized due to HF
were readmitted for HF in the following year [7]. The nu-
merous symptoms of and repeated hospitalizations for HF
negatively affect the patient’s quality of life and increase
the patient’s economic burden [8]. In Sweden, the annual
economic burden attributed to HF was SEK 2.0–2.6
billion, accounting for 2 % of Sweden’s public healthcare
budget [9]. In England, the direct medical costs for HF
treatment accounted for 1.9 % of the entire National
Health Service budget [10]. Since the onset of HF is
strongly correlated with aging [2], the prevalence of HF is
expected to grow worldwide with the aging population
trend.
In South Korea, the number of patients with HF has
been increasing in recent years, with an average annual
increase rate of 4.5 % from 2009 to 2013. In those aged
80 years or above, the reported annual increase rate is
9 %, which is about twice that of the adult population
[11]. In addition, HF is one of the leading causes of
death in South Korea [12]. The aging population rate in
Korea is on a very steep rise, and the percentage of the
population aged 60 years and above is predicted to in-
crease from 13.7 % in 2015 to 28.6 % by 2050 [13]. With
such a rapidly aging population in South Korea, it is ex-
pected that the prevalence of HF and its associated costs
will continue to grow. One useful approach to support-
ing the rationale of allocating healthcare resources to a
specific condition would be to provide information on
the extent to which the patients themselves and our so-
ciety suffer from the burden of that condition. Thus, in
the present study, the prevalence of HF was estimated,
and the impact of HF on the South Korean society was
determined by estimating the economic burden of HF
from the perspectives of the National Health Insurance
(NHI) and the society. Understanding the burden of HF
and identifying the patient subgroups with a higher eco-
nomic burden will aid in the prioritization of healthcare
resource allocation.
Methods
Study design and data source
The economic burden of HF was estimated based on a
“prevalence-based approach,” which measured the costs
associated with treating HF among both new and pre-
existing cases of HF patients in a year [14]. A macro-
costing method was used to investigate the costs of HF
using the 2014 Health Insurance Review and Assessment
Service-National Patients Sample (HIRA-NPS) claims
data (HIRA-NPS-2014-0067). These secondary data in-
clude the claims records for the insurance-covered costs
for the inpatient, outpatient, and emergency department
services, and the prescription drugs of the 3 % random
sample (about 1,400,000 persons) of the entire South
Korean population, which consist of the NHI and Medical
Aid (MA) program enrollees. This set of data was
generated by using a stratified sampling with a stratifica-
tion into two sets of subgroups, namely, sex (2 strata) and
age (16 strata), having a total of 32 strata [15]. In South
Korea, there are two tiers for the universal health security
system. The NHI program is a wage-based, contributory
insurance program covering about 96 % of the population,
while the MA program is a government-subsidized public
assistance program for poor and medically indigent indi-
viduals [16].
Study subjects
Adult patients with HF were defined as those aged ≥19 years
who had at least one NHI or MA claim record of out-
patient or inpatient services with a primary or secondary
diagnosis of HF from the HIRA-NPS claims database in
2014. Due to the fact that HF in patients below 19 years
old is largely attributed to congenital defects, different
pathological etiologies, and lower prevalence rate than in
adults, HF in patients below the age of 19 was ex-
cluded from this study [17]. Based on the literature review
[7, 18–23], the diagnosis codes for HF were identified as
I11.0 (hypertensive heart disease with [congestive] heart
failure), I13.0 (hypertensive heart and renal disease with
[congestive] heart failure), I13.2 (hypertensive heart and
renal disease with both [congestive] heart failure and renal
failure), I50.x (heart failure) as listed in the International
Statistical Classification of Disease and Related Health
Problems 10th Revision (ICD-10 codes) for a base-case
group. In an effort to reflect the patient characteristics
and clinical practice in South Korea, a panel consisting of
three clinicians specializing in cardiology and working in
tertiary-care hospitals in South Korea was consulted. They
were asked about whether the diagnosis codes of HF iden-
tified from the literature are valid for Korean patients with
HF. The clinician panel suggested additional diagnosis
codes (I25.5 [ischemic cardiomyopathy], I42.0 [dilated car-
diomyopathy], and I42.5 [other restrictive cardiomyop-
athy]) to comprehensively capture patients with HF from
the claims records. Thus, to minimize the over- or under-
specification of patients with HF, the patient group was
defined in three different ways: base-case group, narrow-
definition group, and extended-definition group. The pa-
tients in the narrow-definition group have the same diag-
nosis codes of HF as patients in the base case group, with
the former having HF as the primary diagnosis. The pa-
tients in the extended-definition group included base-case
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patients and those who had at least one claim record of
outpatient or inpatient services with a primary or second-
ary diagnosis of I25.5, I42.0, and I42.5 ICD-10 codes. For
each patient group, healthcare utilization associated with
HF was defined as claims records for outpatient, inpatient,
and emergency department services, and prescriptions
with the same diagnosis codes used to define the patient
group.
Estimating the economic burden of HF
The economic burden of HF was estimated both from
the perspective of a payer and of the society. The costs
of HF from a payer’s perspective consisted only of the
NHI- or MA-covered medical costs (hereafter referred
to as “NHI-covered medical costs”). Societal costs
included direct medical and non-medical costs, and in-
direct costs defined as cost of productivity loss due to
morbidity and premature death. Medical costs were
divided into the NHI-covered and non-NHI-covered
costs. The NHI-covered costs were estimated from the
HIRA-NPS claims data. Using data from the Medical
Expenditure Survey provided by NHI Service, the non-
NHI-covered medical costs were estimated using the
ratio of the medical costs for NHI-covered services to
non-NHI-covered services for patients with heart dis-
ease. [11]. Among the non-medical direct costs, the an-
nual per-capita transportation costs were calculated as
the product of the average annual number of outpatient
visits and hospital admissions due to HF per patient and
the average round-trip transportation costs to visit
healthcare institutions, which were obtained from the
2006 Korean National Health and Nutrition Examination
Survey (KNHANES). With the assumption that at least
one family member takes care of the patient during the
latter’s hospitalization or a helper is hired to do such,
the caregiver’s cost was calculated as the product of the
average annual inpatient days per patient due to HF and
the average market price for the daily charge of a helper.
The indirect costs consisted of the productivity loss
costs due to morbidity and mortality and were assigned
for ages under 65 years old, when people are assumed to
be in the labor market. The productivity loss cost due to
morbidity means the opportunity costs of time lost be-
cause of hospitalization or outpatient visits, and was cal-
culated as shown in Eq. (1) based on the human capital
approach [14, 24].
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Iij = average annual inpatient days with a diagnosis of
heart failure (HF) per patient with HF by age and gender
Dij = average daily income by age and gender
Pij = employment rate by age and gender
Oij = average annual number of outpatient visits with a
diagnosis of HF per patient with HF by age and gender
V = average hours per outpatient visit
Hij = average hourly wage by age and gender
The productivity loss cost due to mortality was mea-
sured based on the expected future income foregone as
a result of premature death caused by HF, and was cal-
culated as shown in Eq. (2). The age- and gender-
specific number of deaths attributable to HF (ICD-10
codes of I11.0 and I50.x as a primary diagnosis) was
obtained from the Annual Statistical Report of the Cause
of Death by the Korean National Statistical Office
(KNSO). The average annual income was derived from
the age- and gender-specific average monthly income
from KNSO [14].

















k = 1, 2, …, n (difference between the life expectancy
and age at the time of death)
t = age at the time of death
r = annual discount rate
Nij = number of deaths caused by HF by age and
gender
Yij(t+k) = average annual income at the time of (t + k)
by age and gender
Pij(t+k) = employment rate at the time of (t + k) by age
and gender
The estimated economic burden is presented as the
annual cost per patient with HF and the total national
costs of patients with HF. As the productivity loss cost
due to premature death was estimated based on the total
number of HF deaths in the country instead of applying
the individual risk of death for each patient, it was incor-
porated only in estimating the total national costs. All
costs were expressed in 2016 monetary value.
Sensitivity analysis
Sensitivity analyses were performed for the different ap-
proaches to define the patients with HF. The economic
burden of HF estimated from the base-case patient
group was compared with that estimated from the nar-
row- and extended-definition patient groups. Sensitivity
analysis was also conducted for the mortality rate of HF
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using different data sources. The case definition of HF
death used by the Annual Statistical Report of the Cause
of Death by KNSO was based on the ICD-10 codes of
I11.0 (hypertensive heart disease with [congestive] heart
failure) and I50.x (heart failure) as a primary diagnosis,
which under-identify HF cases compared to the case def-
inition of the base-case patient group (ICD-10 codes of
I11.0, I13.0, I13.2, and I50.x as a primary or secondary
diagnosis) in this study. For the sensitivity analysis, the
results from Roger’s cohort study of 4,537 HF patients
older than 60 years were used [25, 26]. The one-year
mortality rate (male, 20 %; female, 15 %) and the five-
year mortality rate (male, 50 %; female, 46 %) were ex-
tracted from the study for the sensitivity analysis. The
mortality estimates in Roger’s study were calculated
through a review of the medical charts by a panel of
physicians. Compared to the claims data, the mortality
estimates in Roger’s study are more relevant for reflect-
ing the precise and real clinical mortality rate of HF. For
the mortality rate of the HF patients under 60 years, the
same values from the Annual Report on the Cause of
Death Statistics in South Korea were used in the base-
case analysis.
Subgroup analysis
To determine the impact of the disease severity of HF
on the patient’s economic burden, the estimated costs
across the patient subgroups were compared with the
different disease severity levels. The medical costs of the
HF patients younger than 65 and those older than or
equal to 65 were compared. In earlier studies, it was ob-
served that the per-capita utilization and cost of medical
services to treat the same condition was significantly
higher among those enrolled in the MA program in
South Korea than among those enrolled in the NHI pro-
gram [27, 28]. Therefore, the type of national health se-
curity program was considered a risk factor for HF
patients in terms of the disease severity level and the ex-
tent of healthcare utilization. Finally, hospital admission
would be a signal for a severe condition. Thus, the HF
patients were divided into two groups according to ex-
perience of hospitalization, and the medical costs of the
two groups were compared.
Results
Prevalence and healthcare utilization characteristics of
the HF patients
Table 1 presents the epidemiologic and healthcare
utilization characteristics of patients with HF in Korea.
According to the base-case analysis, a total of 475,019
adults (≥19 years old) in South Korea in 2014 were iden-
tified to have HF. The estimated prevalence rate of HF
was 12.4 persons per 1,000 adults. The prevalence of HF
was 9.2 times higher (47.8 vs. 5.2 per 1,000 population)
in the elderly population (≥65 years old) than in the
non-elderly population (19–64 years old). About two-
thirds of the adult HF patients (65.1 %) in the country
were 65 years or older. The highest proportion of HF
Table 1 Characteristics of patients with heart failure in South
Korea in 2014
Characteristics No. of patients (%)
or mean (±SD)
Epidemiologic characteristics
Estimated no. of adult patients (≥19 years old) with
HF in the country
475019
Prevalence per 1000 adult population 12.4
Prevalence per 1000 population (19–64 years old) 5.2













≥ 80 98623 (20.8)




Hospitalization rate (%) of adult patients with HF 12.1
Hospitalization rate (%) of patients (19–64 years old)
with HF
7.1
Hospitalization rate (%) of patients (≥65 years old)
with HF
14.8
No. of outpatient visits per patient 5.01 (±7.33)
No. of hospital admissions per patient 0.24 (±1.07)
No. of inpatient days per patient 3.83 (±26.08)
No. of inpatient days per hospital admission 15.76 (±11.79)
No. of hospital admissions per patient with at least
1 admission
2.01 (±2.42)
No. of inpatient days per patient with at least
1 admission
31.70 (±68.96)
All characteristics listed correspond to results for adult patients aged 19 years
or above unless otherwise specified
HF heart failure, NHI National Health Insurance, MA Medical Aid,
SD standard deviation
aAll healthcare utilizations were defined as outpatient visits or hospital
admissions with a primary or secondary diagnosis code of heart failure (ICD-10
codes of I11.0, I13.0, I13.2, and I50.x)
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patients was observed among those in the 70s (32.7 %),
followed by those in the 60s (21.7 %), 80s or above
(20.8 %), and 50s (16.0 %). Patients under 50 years old
account for only 9.1 % of the adult HF patients. Overall,
more women than men had HF throughout the age
groups (57.7 % vs. 42.3 %). The prevalence of HF across
genders differs, however, depending on the age. Up to
the 60s, men have a higher prevalence of HF than
women, while women have a higher prevalence of HF
than men starting from the 70s (Fig. 1).
On average, the patients with HF had 5.01 outpatient
visits, 0.24 hospital admissions, and 3.83 inpatient days
for HF treatment in a year. About 12 out of 100 HF
patients had hospital admissions due to HF, with 15.76
inpatient days per admission. As age increased, the prob-
ability of hospitalization increased: 14.5 % of the elderly
patients aged 65 or older had hospitalization due to HF
while only 7.1 % of the non-elderly patients had hos-
pitalization due to HF. For the patients with at least one
episode of HF-associated hospitalization, the average
number of annual hospitalizations due to HF, including
the initial hospitalization, was 2.01, and the total number
of inpatient days was 31.70 days.
Socioeconomic burden of HF patients
The average annual medical expenditure for NHI-
covered services spent by individual patients to treat HF
was USD 868.2 in 2014 (Table 2). From the societal per-
spective, the average spending of each patient in 2014
was USD 1,414.0. The total national NHI-covered med-
ical expenditure for the treatment of HF across South
Korea amounted to USD 412.4 million. While only 12 %
of the patients with HF were hospitalized (Table 1), the
medical expenses for inpatient services accounted for
53.4 % of the NHI-covered medical expenditure. From
the societal perspective, the economic burden of HF in
the country was estimated to be USD 752.8 million.
Medical costs accounted for the biggest portion of the
national burden (68.5 % = 54.8 + 13.7 %), followed by the
caregiver’s cost (13.2 %), the productivity loss costs due
to premature death (10.8 %) and morbidity (4.2 %), and
transportation costs (3.4 %).
Sensitivity analyses were performed with varying ap-
proaches to define patients with HF (Table 3). When HF
patients were defined in the most conservative way
(using the narrow definition of patients), the total num-
ber of patients was reduced by 46.1 %, from 475,019 to
256,241 patients. Also, the total national cost was re-
duced by 58.7 %, from USD 752.8 to 311.1 million. On
the other hand, the impact of using the extended defin-
ition of HF patients was marginal, increasing the total
number of patients by only 1.1 %, from 475,019 to
498,783 patients, and increasing the total national cost
by only 9.1 %, from USD 752.8 to 822.0 million. The im-
pact of using different data sources for the mortality rate
of HF was also examined through sensitivity analysis
(Table 3). As both the one- and five-year mortality rates
were higher than the mortality rate reported by the
Annual Statistical Report on the Cause of Death, the
total national costs were increased to USD 878.4 and
1,085.6 million, respectively.
The estimated medical costs substantially varied across
the subgroups that were examined in this study (Table 4).
The elderly patients with HF aged 65 or above spent
about 1.6 times more for NHI-covered medical services
than the non-elderly patients aged 19–64 years old. The
annual per-capita NHI-covered medical cost for treating
HF was 1.6 times higher for the patients enrolled in the
MA program than for those enrolled in the NHI pro-
gram. Finally, compared to the HF patients who had not
experienced hospitalization associated with HF, those
with at least one episode of hospitalization due to HF
Fig. 1 Gender- and age-specific prevalence of heart failure per 1,000 population
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showed 9.7-fold higher NHI-covered medical costs for
treating HF.
Discussion
In this study, the prevalence and economic burden of
the adult HF patients in South Korea were estimated
using the nationally representative HIRA-NPS data,
which cover the insurance claims records of the 3 % ran-
dom sample of the entire population in the country.
Based on the most recent HIRA-NPS data (2014), the
analysis in this study revealed that the estimated preva-
lence rate of HF was 1.24 %. This figure is similar to the
prevalence rate in other countries, such as USA, UK,
Italy, and Denmark, which was reported at approximately
1–2 % [2, 9]. As observed in other countries [29, 30], it
was confirmed that the prevalence of HF also increases
with age in South Korea. The elderly aged 65 or older
showed a 9.2-fold higher prevalence of HF than the non-
elderly population aged 19–64.
Due to the fact that HF is usually accompanied by
many underlying diseases, it is often difficult to identify
the correct cases of HF based on the diagnosis codes
from the insurance claims data. To improve the validity
of the case definition, different approaches to defining
HF cases were carried out in this study: the base-case,
narrow-definition, and extended-definition approaches.
Table 2 Economic burden of heart failure in South Korea in 2014
Per-capita cost, USD Total national cost, million USD
Perspectives Perspectives
Payer Society Payer Society
Total costs (direct and indirect costs) 868.2 (100.0 %) 1414.0 (100.0 %) 412.4 (100.0 %) 752.8 (100.0 %)
Direct costs 1347.8 (95.3 %) 640.2 (85.0 %)
NHI-covered medical costs 868.2 (100.0 %) 868.2 (61.4 %) 412.4 (100.0 %) 412.4 (54.8 %)
Inpatient services (including prescription drug costs) 463.3 (53.4 %) 463.3 (32.8 %) 220.1 (53.4 %) 220.1 (29.2 %)
Outpatient services (including prescription drug costs) 404.9 (46.6 %) 404.9 (28.6 %) 192.3 (46.6 %) 192.3 (25.6 %)
Prescription drug costsa 285.7 (32.9 %) 285.7 (20.2 %) 135.7 (32.9 %) 135.7 (18.0 %)
Non-NHI-covered medical costs - 217.0 (15.3 %) - 103.1 (13.7 %)
Non-medical costs - 262.5 (18.6 %) - 124.7 (16.6 %)
Transportation costs 53.9 (3.8 %) 25.6 (3.4 %)
Caregiver’s costs 208.7 (14.8 %) 99.1 (13.2 %)
Indirect costs - 66.3 (4.7 %) - 112.6 (15.0 %)
PL due to morbidity - 66.3 (4.7 %) - 31.5 (4.2 %)
PL due to premature death - - - 81.1 (10.8 %)
All costs were expressed in 2016 monetary value (1 USD = 1,150 Korean won)
USD U.S. dollar, NHI National Health Insurance, PL productivity loss
aPrescription drug costs were calculated as the sum of inpatient and outpatient prescription drug costs
Table 3 Sensitivity analysis results by varying the definition of





Base case (N = 475019 patients) 1414.0 752.8
Definition of patient
Narrow definition
(N = 256241 patients)
948.8 311.1
Extended definition
(N = 498783 patients)
1560.5 822.0
Mortality rate
1-year mortality - 878.4
5-year mortality - 1085.6
USD U.S. dollar
All costs were expressed in 2016 monetary value (1 USD = 1,150 Korean won)
and estimated from a societal perspective





19–64 years old 629.5 1.0
≥ 65 years old 996.0 1.6
By type of health security program enrolled in
NHI 821.1 1.0
MA 1310.9 1.6




Hospitalized in 2014 4104.4 9.7
USD U.S. dollar, NHI National Health Insurance, MA medical aid
All costs were expressed in 2016 monetary value (1 USD = 1,150 Korean won)
and estimated from the payer’s perspective
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While the estimated number of HF patients identified
according to the extended definition of HF increased
only by 1.1 % from the base-case patients, it decreased
by 46.1 % when the narrow definition of HF patient was
used. The difference in the method of identifying HF pa-
tients between the narrow and base-case definitions
comes from whether only the primary diagnosis was
used or both the primary and secondary diagnoses were
used to define the cases using the same ICD-10 codes
(I11.0, I13.0, I13.2, and I50.x). As a result of the use only
of the primary diagnosis in the narrow-definition group,
the total number of HF patients in the country was re-
duced to about half of the base-case patient groups,
which used both the primary and secondary diagnoses
to define HF patients. To determine which approach is
more valid for capturing HF cases, we examined the pri-
mary diagnoses of those identified as HF patients based
on their secondary diagnosis. About 75 % of the primary
diagnoses of the patients were conditions related to HF,
such as hypertension (33.6 %), angina pectoris (10.3 %),
non-insulin-dependent diabetes mellitus (9.4 %), atrial
fibrillation and flutter (6.6 %), chronic kidney disease
(6.2 %), and chronic ischemic heart disease (2.7 %)
(Table 5). As a result, it appears that the narrow defin-
ition would cause under-specification for HF cases.
Thus, based on the base case and the extended defin-
ition of cases, it is reported that the annual economic
burden of HF from the societal perspective ranges from
USD 1,414.0 to 1,560.5 for individual patients, and from
USD 752.8 to 1,085.6 million for the entire country.
As mentioned earlier (in the Background section), pa-
tients with HF have a high risk of hospitalization. This is
reflected in the cost estimation results of this study. The
inpatient services accounted for 53.4 % of the NHI-
covered medical costs for the individual patients with
HF (Table 2). Compared to other chronic diseases that
are common among the elderly such as hypertension
(18.3 %), diabetes (36.4 %), rheumatic arthritis (18.9 %),
and respiratory disorder (49.5 %) including asthma,
COPD, and emphysema, HF (53.4 %) incurred higher
spending for inpatient services in 2014 [24]. Also, pa-
tients who had experienced hospitalization with HF in-
curred about ten times higher NHI-covered medical
costs (Table 4). These findings suggest that effective
intervention to prevent hospital admission would be a
critical component of the disease management strategy
for patients with HF to minimize the economic and clin-
ical burden of HF.
The higher costs occurred among the MA patients
than the NHI patients. This was explained by the dif-
ferences in hospitalization rate and proportion of the
elderly between the two groups. The proportion of the
HF patients experiencing hospitalization is approxi-
mately 1.7 times higher in the MA patients (19.2 %) than
the NHI patients (11.3 %). In addition, the higher
proportion of the elderly aged 70 years and above is
observed among the MA patients (64.2 %) than the NHI
patients (52.4 %).
As in most other illnesses, the elderly patients seemed
to require more healthcare resources to treat HF com-
pared to the younger patients. Those aged 65 or above
in this study spent about 1.6 times more NHI-covered
medical costs than those aged 19–64. The higher med-
ical spending among the elderly group may be partly
attributable to the higher risk of hospitalization that
comes with aging. The hospitalization rate of those aged
65 or above among the study subjects was about twice
that of those aged 19–64 (14.8 % vs. 7.1 %).
With the NHI claims data recently made available to
the general public in South Korea for research purposes,
there are ongoing researches on the cost of the illness,
but most of the researches on HF are focused on pri-
mary diagnoses or with a narrowly defined scope of HF,
posing restrictions on the accurate estimation of the cost
of HF. In contrast, some studies have been conducted in
hospital settings. According to a previous study con-
ducted using electronic medical chart review for HF
patients from tertiary-care hospitals, the average cost
per hospitalization with HF was estimated to be approxi-
mately USD 7,000 [31], which is 1.7 times higher than
what was estimated in this study (USD 4,140). The dif-
ference in the estimated hospitalization cost is attribut-
able to the fact that the previous study limited the study
subjects to the patients with acute HF in the tertiary
hospitals.
This study has the potential risk of underestimating
the cost of HF for the following reasons. First, in calcu-
lating the transportation costs incurred for an outpatient
visit or for hospital admission, only the patient’s trans-
portation costs were included. It was possible, however,
that at least one caregiver accompanied a patient when
Table 5 Distribution of primary diagnoses of base-case patients
identified as having heart failure based on the secondary diagnosis
Rank ICD-10 code Description Percent
1 I10 Essential (primary) hypertension 33.59
2 I20 Angina pectoris 10.26
3 E11 Non-insulin-dependent diabetes mellitus 9.41
4 I48 Atrial fibrillation and flutter 6.61
5 N18 Chronic kidney disease 6.21
6 I25 Chronic ischemic heart disease 2.70
7 I42 Cardiomyopathy 1.97
8 I21 Acute myocardial infarction 1.81
9 I63 Cerebral infarction 1.58
10 E14 Unspecified diabetes mellitus 1.27
Total 75.41
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he/she visited the hospital on an outpatient basis or was
admitted to a hospital because about 64 % of HF patients
are aged 65 years or above who require assistance from
others. Second, based on the human capital approach, the
productivity loss costs due to morbidity and premature
death were accounted for only for those under 65 years
old, with the assumption that those above 65 years old are
no longer productive and no longer contribute to the soci-
ety. This leads to underestimation of costs as well as the
ethical problem of not ascribing any value to the latter
years of life. Third, to overcome the tendency to under-
estimate premature death costs caused by under-specified
HF death from the national death statistics, sensitivity
analysis was conducted using the one- and five-year mor-
tality rates of HF patients based on existing relevant litera-
ture. However, the use of the literature value was limited
to only those who were ≥60 years old. Thus, there is still a
possibility of underestimating premature death costs for
cases of patients under 60 years old.
This study also has a potential to overestimate the
economic burden of HF. In calculating the productivity
loss costs due to morbidity and mortality, a 100 % em-
ployment rate was assumed for those under 65 years old.
This does not imply that all the HF patients are
employed. The rationale for this assumption is that the
time of the HF patients who are not part of the labor
market should not be undervalued compared to that of
patients who are part of the labor market. If it is insisted
that productivity loss can occur only for those who are
part of the labor market, the proposed approach may
overestimate the costs.
Conclusions
This study presented the extent of the economic burden at-
tributable to heart failure (HF) in the South Korean society.
The prevalence rate of HF in 2014 was 12.4 out of 1000
adults, while the annual socioeconomic cost of HF was esti-
mated to be 752.8 million USD. The onset of HF is posi-
tively correlated with aging. Due to the extended life
expectancy, the prevalence of HF, accumulated from the
long-term survivors, is expected to grow continuously. As
such, HF has drawn special attention in the existing aging
society. In this study, HF patients who were older and had
a history of prior hospitalization with HF as well as an indi-
gent status (i.e., enrolled in the Medical Aid [MA] program)
were shown to be at high risk to spend more for healthcare
to treat their HF. An effective disease management protocol
should be employed to target such patient group.
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